CORDIS - Forschungsergebnisse der EU
CORDIS
Inhalt archiviert am 2024-05-24

Development of cdna-arrays for quantifying expression levels of mrna and oligo-arrays for detecting genetic variants of drug metabolism genes: pharmagenarrays

Ziel

The scientific goals of the proposed prom act are:
1) To develop a array-array system to profile expression levels of drug metabolising enzymes after exposure of cell cultures or whole animals to xenobiotics (drugs or environmental compounds) and
2) to develop an oligonucleotide-array system to detect variant alleles of genes that determine an individuals response to medicinal compounds (drugs) or determine an individuals risk on exposure to environmental toxins. Expression profiling of drug metabolising enzymes in animals and later in humans is a key component in the pre-clinical stages of new drug development in the pharmaceutical industry. Detection of variant alleles (genotyping), the second objective of the proposed collaboration, will address an emerging and far-reaching need in the pharmaceutical industry and in healthcare in general. The ultimate goal of this second objective is to develop a cost-effective method of pharmacogenetic profiling for use as a tool in clinical trial studies and in the longer term as a means of selecting the lost aoorioriate drug therapy for individual patients.

Aufforderung zur Vorschlagseinreichung

Data not available

Finanzierungsplan

EAW - Exploratory awards

Koordinator

METABOLIC SYSTEMS CO
EU-Beitrag
Keine Daten
Adresse
c/o Biochemistry Dept., Trinity College
DUBLIN
Irland

Auf der Karte ansehen

Gesamtkosten
Keine Daten

Beteiligte (1)